Immunocore Holdings Ltd (IMCR) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Immunocore Holdings Ltd stock $24.50, price $28.88, that is 15.2% below the price, quality 40 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Immunocore Holdings Ltd
IMCR · USExpensive (fair value 15% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range $18.94 – $75.36 · fair‑value band $18.37 – $30.62 · the $28.88 price screens above the $24.50 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Immunocore Holdings is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally.
Show moreShow less
The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.
It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus.
Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Stock analysis
Immunocore Holdings Ltd (IMCR) currently trades at $28.88, while our estimate is $24.50, 15% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $18.37 (bear) to $30.62 (bull), the price of $28.88 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Immunocore Holdings Ltd reported revenue of £298M in FY2025 versus £27.0M in FY2021, a compound +82.1%/yr. Reported net income was −£26.4M in FY2025.
Key figures
Market cap $1.5B Small · P/S ratio 3.70 · EPS (TTM) $−0.6400 · Net margin −8.9% · Return on equity −4.5% · Return on assets (EBIT) −11.3% (5-year average) · Operating margin −2.6% · Revenue (TTM) $431M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 13 out of 100 (medium confidence).
What moves the price
The share trades about 28% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −15%, IMCR screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, no officer or director bought or sold shares on the open market.
- SaleBahija JallalCHIEF EXECUTIVE OFFICER, Director11,474 shares at $32.35$371,184Feb 18, 2026
- SaleJohn GollSVP, FINANCE & CAO698 shares at $32.35$22,580Feb 18, 2026
- SaleDavid M BermanHEAD OF R&D4× since Nov 24, 2025: 130,923 shares, avg. $39.79$5.2MFeb 18, 2026
- SaleTina Amber St LegerCHIEF HR OFFICER1,000 shares at $32.35$32,350Feb 18, 2026
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Compare Immunocore Holdings Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- P/S ratio by industry
- EBIT margin by industry
- Stock screener with 62 metrics
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs IMCR |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs IMCR |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs IMCR |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs IMCR |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs IMCR |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs IMCR |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs IMCR |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs IMCR |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs IMCR |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs IMCR |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Immunocore Holdings Ltd (IMCR) overvalued or undervalued?
What is the fair value of IMCR?
What is the quality score of IMCR?
What is the price target for Immunocore Holdings Ltd (IMCR)?
What is the Immunocore Holdings Ltd stock forecast for 2026?
What is the revenue of Immunocore Holdings Ltd (IMCR)?
What is the intrinsic value of Immunocore Holdings Ltd (IMCR)?
Is Immunocore Holdings Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of IMCR?
How much is Immunocore Holdings Ltd worth?
What do the bullish and bearish scenarios say about IMCR?
How solid is the balance sheet of Immunocore Holdings Ltd (IMCR)?
How far is IMCR from its 52-week high?
Which stocks are comparable to Immunocore Holdings Ltd?
Is Immunocore Holdings Ltd stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Immunocore Holdings Ltd (IMCR)?
What should I pay attention to with Immunocore Holdings Ltd right now?
Key figures of Immunocore Holdings Ltd
How large is the market capitalisation of Immunocore Holdings Ltd (IMCR)?
What is the P/S ratio of Immunocore Holdings Ltd (IMCR)?
What are the earnings per share of Immunocore Holdings Ltd (IMCR)?
What is the net margin of Immunocore Holdings Ltd (IMCR)?
What is the return on equity of Immunocore Holdings Ltd (IMCR)?
What is the EBIT return on assets of Immunocore Holdings Ltd (IMCR)?
What is the operating margin of Immunocore Holdings Ltd (IMCR)?
How fast is revenue growing at Immunocore Holdings Ltd (IMCR)?
How fast are earnings growing at Immunocore Holdings Ltd (IMCR)?
How much free cash flow does Immunocore Holdings Ltd (IMCR) generate?
How much net cash does Immunocore Holdings Ltd (IMCR) hold?
Watch Immunocore Holdings Ltd in the live analysis
One click puts Immunocore Holdings Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.